FAYE M JOHNSON to Disease-Free Survival
This is a "connection" page, showing publications FAYE M JOHNSON has written about Disease-Free Survival.
Connection Strength
0.201
-
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 2016 Jul 26; 7(30):47998-48010.
Score: 0.058
-
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther. 2012 Sep; 11(9):2021-32.
Score: 0.044
-
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Oct 20; 28(30):4609-15.
Score: 0.039
-
Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck. 2017 04; 39(4):633-638.
Score: 0.015
-
Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. 2016 06 01; 122(11):1702-7.
Score: 0.014
-
Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck. 2013 Oct; 35(10):1454-60.
Score: 0.011
-
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
Score: 0.010
-
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15.
Score: 0.009